The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
UHS · Healthcare · Narrow moat
Wonderful & reasonably priced
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
SI · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
CARL · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
NVAX · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | UHS | SI | CARL | NVAX |
|---|---|---|---|---|
| Moat Score (0–100) | 67 (highest) | 67 (highest) | 67 (highest) | 66 |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 96 (highest) | 70 | 70 | 72 |
| Pricing power | — | 100 (highest) | 100 (highest) | 76 |
| Returns on capital | 25 | — | — | — |
| Balance-sheet safety | 58 | 55 | 55 | 73 (highest) |
| Capital discipline | 88 (highest) | 44 | 44 | 44 |
| Price vs. high estimate | 46% below high estimate | No price data | No price data | No price data |
| Market cap | $9.7B | $432.9M | $301.4M | $1.3B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |